Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Raghav on Sequencing Therapies for Resectable Versus Unresectable CRC

January 26th 2021

Kanwal Raghav, MBBS, MD, discusses his approach to sequencing therapies for patients with resectable and unresectable colorectal cancer.

Postoperative MRD Positivity Linked With Reduced RFS in CRC

January 26th 2021

January 26, 2021 — Patients with colorectal cancer who had molecular residual disease positivity immediately after surgery were found to have a high risk of disease recurrence and longitudinal monitoring increased the predictive power of circulating tumor DNA.

Frontline Pembrolizumab Approved in Europe for Metastatic MSI-H/dMMR CRC

January 26th 2021

January 26, 2021 - The European Commission has approved single-agent pembrolizumab for use in the frontline treatment of patients with metastatic microsatellite instability–high or mismatch repair deficient colorectal cancer.

Dr. Marshall on Changes With Adjuvant Treatment in CRC

January 25th 2021

John L. Marshall, MD, discusses recent changes to the adjuvant treatment landscape in colorectal cancer.

Dr. Strickler on Dosing Regorafenib in CRC

January 25th 2021

John H. Strickler, MD, discusses dosing strategies with regorafenib in colorectal cancer.

Dr. Dasari on the Potential Clinical Implications of Fruquintinib in mCRC

January 25th 2021

Nageshwara Arvind Dasari, MD, discusses the potential clinical implications with fruquintinib in metastatic colorectal cancer.

Big Data Tool Finds Variations in Treatment and Costs Across 3 Cancer Types

January 25th 2021

Using real-world data from more than 4000 patients with common cancers, an algorithm was able to detect variations in care that, if reduced, could result in a median savings of $26,773 per patient.

Dr. Hubbard on Sequencing Challenges With EGFR Inhibitors in CRC

January 22nd 2021

Joleen M. Hubbard, MD, discusses sequencing challenges regarding EGFR inhibitors in colorectal cancer.

Dr. Bekaii-Saab Discusses Indicators of Progression in CRC

January 22nd 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses indicators of progression in colorectal cancer.

First-Line Options in mCRC

January 22nd 2021

Axel Grothey, MD, and John Marshall, MD, discuss first-line treatment options in patients with metastatic colorectal cancer.

Treatment Considerations in mCRC

January 22nd 2021

Axel Grothey, MD, discusses factors that influence treatment selection in patients with mCRC.

Dr. Ahn on the Growing Role of ctDNA as a Biomarker in CRC

January 21st 2021

Daniel H. Ahn, DO, discusses the growing role of circulating tumor DNA in colorectal cancer.

Dr. Lwin on Patient Selection for LEAP-005 Study in CRC, Biliary Tract Cancer, and More

January 20th 2021

Zarnie Lwin, MBBS, FRACP, discusses patient selection, including those with colorectal cancer, for the phase 2 LEAP-005 study.

Dr. Lenz on the Promise of ctDNA in the mCRC Treatment Paradigm

January 20th 2021

Heinz-Josef Lenz, MD, FACP, discusses the promise of circulating tumor DNA in colorectal cancer.

Dr. Pandalai on Outcomes With Adjuvant HIPEC in CRC

January 19th 2021

Prakash Pandalai, MD, discusses outcomes with adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer.

Dr. Raghav on the Role of Molecular Profiling in Treatment Selection in mCRC

January 18th 2021

Kanwal Raghav, MBBS, MD, discusses the role of molecular profiling in treatment selection for patients with metastatic colorectal cancer.

TAS-102 Plus Bevacizumab Improves OS in mCRC Ineligible for Intensive Therapy

January 17th 2021

January 16, 2021 - Trifluridine/tipiracil, when used in combination with bevacizumab, led to an improvement in overall survival over capecitabine/bevacizumab in the frontline treatment of patients with unresectable metastatic colorectal cancer who are not eligible for standard chemotherapy.

Frontline Pembrolizumab Improves PFS2, HRQoL in MSI-H/dMMR mCRC

January 16th 2021

January 16, 2021 - Frontline use of pembrolizumab monotherapy significantly improved progression-free survival, while demonstrating superior safety, compared with chemotherapy in patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer.

Lenvatinib and Pembrolizumab Combination Safe, Effective For Multiple Gastrointestinal Cancer Types

January 15th 2021

The combination of the anti-angiogenic multikinase inhibitor lenvatinib plus the anti-PD-1 antibody pembrolizumab demonstrated promising antitumor activity and a manageable safety profile in previously treated patients with advanced gastric cancer, advanced metastatic microsatellite instability-high or mismatch repair colorectal cancer, and advanced biliary tract cancers

Health-Related Quality of Life Scores in Young CRC Survivors Are Low and Require Targeted Intervention

January 15th 2021

January 15, 2021 - As the incidence of colorectal cancer in patients under 50-years-old increases, overall health-related quality of life among younger survivors is poorer, with social and functional well-being suffering more as treatment duration grows longer.